Item 1.01 | Entry into a Material Definitive Agreement. |
On January 15, 2025, Li-Cycle Holdings Corp. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis” or the “Underwriter”), pursuant to which the Company agreed to offer and sell, in an underwritten public offering in the United States (the “Offering”), an aggregate of (i) 5,000,000 units (the “Units”), each consisting of (a) one common share, without par value, of the Company (each, a “Common Share”), (b) one eight-month warrant to purchase one Common Share (the “Series A Warrants”) and (c) one five-year warrant to purchase one Common Share (the “Series B Warrants”) and (ii) in lieu of Units, 10,000,000 pre-funded units (the “Pre-Funded Units”), each consisting of (a) one pre-funded warrant to purchase one Common Share (the “Pre-Funded Warrants” and, together with the Series A Warrants and the Series B Warrants, the “Warrants”), (b) one Series A Warrant and (c) one Series B Warrant.
The public offering price per Unit is $1.00 and the public offering price per Pre-Funded Unit is $0.99999, which is equal to the public offering price per Unit minus the exercise price of $0.00001 per Pre-Funded Warrant. The initial exercise price of each Series A Warrant is $1.00 per Common Share. The Series A Warrants will be immediately exercisable and will expire on the eight-month anniversary of the initial date of issuance of the Series A Warrants. The initial exercise price of each Series B Warrant is $1.00 per Common Share. The Series B Warrants will be immediately exercisable and will expire on the five-year anniversary of the initial date of issuance of the Series B Warrants.
Additionally, the Company granted Aegis a 45-day option to purchase up to 2,250,000 additional Common Shares (15.0% of the Common Shares included in the Units and the Pre-Funded Units sold in the Offering), at a price of $0.99998 per Common Share; and/or up to 2,250,000 additional Series A Warrants to purchase an aggregate of an additional 2,250,000 Common Shares (15.0% of the Series A Warrants included in the Units and Pre-Funded Units sold in the Offering) at a price of $0.00001 per Series A Warrant; and/or up to 2,250,000 additional Series B Warrants to purchase an aggregate of an additional 2,250,000 Common Shares (15.0% of the Series B Warrants included in the Units and Pre-Funded Units sold in the Offering) at a price of $0.00001 per Series B Warrant. The Underwriter may exercise this option with respect to the Common Shares only, Series A Warrants only, Series B Warrants only, or any combination thereof. On January 16, 2025, Aegis exercised its over-allotment option with respect to 2,250,000 Series A Warrants and 2,250,000 Series B Warrants.
The Offering was made pursuant to that certain Registration Statement on Form S-3 (File No. 333-278010), which was filed on March 15, 2024 and declared effective by the Securities and Exchange Commission (“SEC”) on March 29, 2024, including the prospectus contained therein and a prospectus supplement dated January 15, 2025, filed with the SEC on January 16, 2025.
In connection with the Offering, on January 14, 2025, the Company entered into a letter agreement with Glencore Canada Corporation (“Glencore”) (the “Glencore Consent and Waiver Agreement”), a related party of the Company and the holder of the senior secured convertible note dated as of March 25, 2024 issued by the Company (the “Glencore Senior Secured Convertible Note”), pursuant to which Glencore has, among other things, granted its consent to the issuance by the Company of the Warrants and agreed to waive any default or event of default under the Glencore Senior Secured Convertible Note which may occur as a result of the issuance of the Warrants and the Company’s compliance with the terms of the Warrants relating to (i) the participation by the holders of the Warrants in certain dividends and other distributions declared by the Company to the holders of the Common Shares (under the terms of the Warrants), and (ii) the payment of cash or non-cash consideration upon the repurchase or exercise of Warrants in connection with a Fundamental Transaction (as defined in the Warrants) so long as, to the extent any of the Glencore Notes (as defined below) are outstanding immediately prior to the occurrence of a Fundamental Transaction, the Company shall have complied with its obligations to redeem the Glencore Notes in accordance with their terms in connection with such Fundamental Transaction prior to the Company paying cash or non-cash consideration to the holders of the Warrants. In addition, the Company has